LYZ and infection: With this purpose, the study of Brunaugh and coworkers report the development of an inhalable formulation of niclosamide associated with lysozyme, which helps the solubilization and delivery to the primary sites of infection of coronaviruses at high dose concentrations and improves the antiviral potency of niclosamide in vitro and in vivo against MERS-CoV and SARS-CoV-2 infection using a murine model [160].